SK Biopharmaceuticals
SK Biopharmaceuticals, a leading player in the biopharmaceutical industry, is headquartered in South Korea (KR) and operates extensively across Asia, Europe, and North America. Founded in 2011, the company has rapidly established itself as a pioneer in developing innovative therapies for neurological disorders, particularly epilepsy. With a strong focus on research and development, SK Biopharmaceuticals has achieved significant milestones, including the successful launch of its flagship product, cenobamate, which offers unique mechanisms of action for seizure control. The company is recognised for its commitment to advancing healthcare solutions, positioning itself as a key contributor to the global biopharmaceutical landscape. Through its dedication to innovation and patient-centric approaches, SK Biopharmaceuticals continues to enhance its market presence and reputation.
DitchCarbon Score
How does SK Biopharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SK Biopharmaceuticals's score of 14 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SK Biopharmaceuticals's reported carbon emissions
In 2023, SK Biopharmaceuticals reported total carbon emissions of approximately 1,479,000 kg CO2e, comprising 433,000 kg CO2e from Scope 1, 1,046,000 kg CO2e from Scope 2, and 11,882,000 kg CO2e from Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, including significant contributions from upstream activities. Over the years, the company has demonstrated a commitment to reducing its carbon footprint. In 2022, total emissions were about 1,479,000 kg CO2e, with Scope 1 emissions at 425,000 kg CO2e and Scope 2 at 936,000 kg CO2e. The Scope 3 emissions for that year were reported at 6,547,000 kg CO2e, indicating a substantial area for potential improvement. Despite the absence of specific reduction targets or initiatives disclosed, SK Biopharmaceuticals is actively engaged in monitoring and reporting its emissions across all relevant scopes. The company’s emissions intensity metrics, such as Scope 2 emission intensity per employee, have been tracked, with values indicating a focus on efficiency relative to revenue and workforce size. Overall, SK Biopharmaceuticals is positioned within the biopharmaceutical industry, which is increasingly prioritising sustainability and climate commitments, although specific reduction targets have not been outlined in the available data.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 518,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 56,834,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 3 | 4,913,000 | - | - | - | - | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SK Biopharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
